Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ", <20 p" to ", fewer than 20 p") |
|||
(One intermediate revision by one other user not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | {{#lst: | + | {{#lst:Editorial board transclusions|heme}} |
'''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | '''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
Line 25: | Line 25: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Plerixafor (Mozobil)]] | + | *[[Plerixafor (Mozobil)]] 0.01 to 0.02 mg/kg SC twice per day |
+ | '''Various durations''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30625055/ PubMed] | + | # '''Case series:''' McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/30625055/ PubMed] |
[[Category:WHIM syndrome regimens]] | [[Category:WHIM syndrome regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Cytopenias]] | [[Category:Cytopenias]] |
Latest revision as of 13:28, 5 November 2023
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
Regimen
Study | Evidence |
---|---|
McDermott et al. 2019 | Pilot, fewer than 20 pts |
References
- Case series: McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article contains dosing details in manuscript PubMed